52.14

4.16% 2.08

After Hours: 52.17 0.03 +0.06%

Corcept Therapeutics Inc (CORT)

Overview News Price History Option Chain Financials Why CORT Down? Discussions Forecast

Corcept Therapeutics Inc stock is traded at $52.14, with a volume of 1.22M. It is up +4.16% in the last 24 hours and up +14.77% over the past month. Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Previous Close:

$50.06

Open:

$50

24h Volume:

1.22M

Relative Volume:

1.46

Market Cap:

$5.34B

Revenue:

$523.53M

Net Income/Loss:

$118.02M

P/E Ratio:

64.37

EPS:

0.81

Net Cash Flow:

$124.84M

1W Performance:

+8.15%

1M Performance:

+14.77%

6M Performance:

+112.64%

1Y Performance:

+103.51%

1-Day Range:

$49.51

$52.35

1-Week Range:

$42.01

$52.35

52-Week Range:

$20.84

$52.35

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name

Corcept Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (680)

Phone

650.688.8803

Address

149 COMMONWEALTH DRIVE, MENLO PARK

Employee

352

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

CORT's Discussions on Twitter

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-06-23	Upgrade	Truist	Hold → Buy
Apr-11-23	Initiated	SVB Securities	Market Perform
Apr-04-23	Initiated	Piper Sandler	Overweight
Feb-15-23	Downgrade	Jefferies	Buy → Hold
Aug-01-22	Downgrade	Truist	Buy → Hold
Jul-27-22	Upgrade	Jefferies	Hold → Buy
Jun-27-22	Resumed	Canaccord Genuity	Buy
Feb-02-22	Initiated	Canaccord Genuity	Buy
Jan-28-22	Initiated	Truist	Buy
Aug-05-20	Downgrade	Jefferies	Buy → Hold
Sep-24-19	Initiated	Jefferies	Buy
Sep-06-19	Initiated	H.C. Wainwright	Buy
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral
Aug-10-18	Reiterated	Stifel	Hold
May-31-18	Downgrade	Stifel	Buy → Hold
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy
Aug-31-17	Initiated	Stifel	Buy
Feb-02-17	Initiated	Ladenburg Thalmann	Buy
Apr-21-15	Initiated	FBR Capital	Outperform
Jan-13-14	Downgrade	Stifel	Buy → Hold
Aug-09-13	Downgrade	Janney	Buy → Neutral
Aug-09-13	Downgrade	Ladenburg Thalmann	Buy → Neutral
Feb-21-12	Reiterated	JMP Securities	Mkt Outperform
Jan-06-10	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jul-17-08	Initiated	Rodman & Renshaw	Mkt Outperform
Jun-21-07	Upgrade	Punk, Ziegel & Co	Mkt Perform → Accumulate

View All

Corcept Therapeutics Inc Stock (CORT) Latest News

12:45 PM

Here is Why Growth Investors Should Buy Corcept (CORT) Now - Yahoo Finance

12:45 PM

12:00 PM

Corcept (CORT) Upgraded to Strong Buy: Here's Why - Yahoo Finance

12:00 PM

09:15 AM

Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance Australia

09:15 AM

09:04 AM

Corcept Stock At New High; Will The Upcoming Regulatory And Clinical Trial Catalysts Take It Higher? - RTTNews

09:04 AM

05:42 AM

Roman Butler Fullerton & Co. Sells 10,466 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat

05:42 AM

03:11 AM

Creative Planning Acquires 841 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

03:11 AM

Nov 04, 2024

Corcept Therapeutics (NASDAQ:CORT) Reaches New 1-Year HighStill a Buy? - MarketBeat

Nov 04, 2024

Corcept Therapeutics stock soars to all-time high of $50.23 By Investing.com - Investing.com Australia

Nov 04, 2024

Corcept Therapeutics stock soars to all-time high of $50.23 - Investing.com

Nov 04, 2024

Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade - Yahoo Canada Finance

Nov 04, 2024

Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why - Yahoo Canada Finance

Nov 04, 2024

Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.2%Here's What Happened - MarketBeat

Nov 01, 2024

FY2026 Earnings Estimate for CORT Issued By HC Wainwright - MarketBeat

Nov 01, 2024

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024

Corcept’s relacorilant GRADIENT trial misses primary endpoint - Yahoo Finance

Nov 01, 2024

Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 01, 2024

Oct 31, 2024

Earnings call: Corcept Therapeutics reports robust Q3 growth, raises guidance - Investing.com Canada

Oct 31, 2024